女性特异性恶性肿瘤中的血栓形成:从化疗驱动风险到预防与药物相互作用
本文综述乳腺癌、卵巢癌、子宫内膜癌和宫颈癌等女性特异性恶性肿瘤相关的癌症相关血栓(CAT)证据,重点讨论化疗与激素相关风险、血栓预防策略及抗凝药选择中的药理学考量,强调以患者为中心的多学科药物治疗管理。
要点
- 卵巢癌静脉血栓栓塞发生率最高,为5%至14%,与晚期疾病、腹水及铂类化疗相关。
- 乳腺癌约占所有CAT病例的15%,使用选择性雌激素受体调节剂或CDK4/6抑制剂者风险增加。
- API-CAT试验中减剂量阿哌沙班(2.5 mg每日两次)在6个月治疗后延长抗凝中非劣于全剂量。
核心结论
- 女性特异性恶性肿瘤具有由激素、解剖及治疗相关因素驱动的独特血栓特征。
- 以患者为中心、多学科协作的药物治疗方法对优化血栓预防和减少出血风险至关重要。
研究设计与样本
- 本文为综述,总结女性特异性恶性肿瘤中癌症相关血栓的当前证据。
主要发现
- 卵巢癌静脉血栓栓塞发生率为5%至14%,主要与晚期疾病、腹水和铂类化疗相关。
- 乳腺癌约占所有CAT病例的15%,使用选择性雌激素受体调节剂或细胞周期蛋白依赖性激酶4/6抑制剂者风险增加。
- 子宫内膜癌具有中至高度CAT风险,尤其在肥胖患者及接受激素治疗或放疗者中。
关键数值与推荐
- 低分子量肝素或直接口服抗凝药预防可有效降低高危患者的VTE发生率。
- API-CAT试验中减剂量阿哌沙班(2.5 mg每日两次)在6个月治疗后延长抗凝非劣于全剂量(2.1% vs. 2.8%;校正亚风险比0.76;95%CI 0.58-0.97;p=0.001)。
- 与多柔比星、瑞波西利和他莫昔芬等药物的相互作用需要个体化抗凝选择和密切监测。
临床怎么用
- 对高危女性特异性恶性肿瘤患者应考虑低分子量肝素或直接口服抗凝药进行血栓预防。
- 使用与抗凝药有相互作用的化疗或内分泌药物时,应个体化选择抗凝药并密切监测。
- 延长抗凝阶段可考虑减剂量阿哌沙班方案,但需结合患者出血风险综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer-associated thrombosis (CAT) remains a leading cause of morbidity and mortality among patients with cancer. Female-specific malignancies such as breast, ovarian, endometrial, and cervical cancers exhibit distinct thrombotic profiles driven by hormonal, anatomical, and treatment-related factors. This review summarizes current evidence on CAT in these malignancies, emphasizing chemotherapy- and hormone-related risk, thromboprophylactic strategies, and pharmacologic considerations in anticoagulant selection. Ovarian cancer carries the highest incidence of venous thromboembolism (VTE), ranging from 5% to 14%, largely due to advanced disease, ascites, and platinum-based chemotherapy. Breast cancer accounts for approximately 15% of all CAT cases, with increased risk observed among patients treated with selective estrogen receptor modulators or cyclin-dependent kinase 4/6 inhibitors. Endometrial cancer presents a moderate to high risk for CAT, especially in obese patients and those receiving hormonal therapy or radiation. Prophylaxis with low-molecular-weight heparins (LMWHs) or direct oral anticoagulants (DOACs) effectively reduces VTE incidence in high-risk patients. In the API-CAT trial, reduced-dose apixaban (2.5 mg twice daily) was non-inferior to full-dose therapy for extended anticoagulation after 6 months of treatment (2.1% vs. 2.8%; adjusted subhazard ratio, 0.76; 95% Confidence Interval (CI), 0.58-0.97; p = 0.001). Drug-drug interactions with anticoagulants and agents such as doxorubicin, ribociclib, and tamoxifen warrant individualized anticoagulant selection and close monitoring. A patient-centered pharmacotherapeutic approach, supported by multidisciplinary collaboration, is essential to optimize thrombosis prevention and minimize bleeding risk in women with cancer.
引用
- Aghakouchakzadeh M, Kakavand H, Goldberg AJ, et al. Thrombosis Across Female-Specific Malignancies: From Chemotherapy-Driven Risk to Prophylaxis and Drug Interactions. Pharmacotherapy. 2026. PMID: 41998827. doi:10.1002/phar.70149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。